Advances in therapeutic radiation delivery coupled with improved systemic therapy, including targeted agents and immunotherapy, are revolutionizing the oncology landscape. Emerging multi-modality treatments have increased control rates for virtually all cancers and in some cases have rendered durable remissions for patients with advanced and metastatic disease. This revolution has emerged in large part from comprehensive tumor molecular profiling efforts and has led to the development of novel minimally invasive biomarkers -- an essential tool in guiding future personalized therapy.
In this webcast, we will review the recent history of molecular profiling in genitourinary cancers and discuss the utility of novel minimally invasive biomarkers in both patient selection and treatment delivery. We will focus on prostate and bladder cancer and review recent advances, strategies for improved delivery of radiotherapy in the era of personalized oncology, and ongoing challenges and opportunities.
Omar Y. Mian MD, Phd, Assistant Professor, Cleveland Clinic Lerner College of Medicine, Associate Staff Physician, Dept of Radiation Oncology, Department of Translational Hematology and Oncology Rsearch, Cleveland Clinic Foundation, Cleveland, OH
Dr. Mian is a Radiation Oncologist and Physician Scientist in the Department of Translational Hematology and Oncology Research (THOR) at the Cleveland Clinic. His clinical specialty is genitourinary tract cancers (bladder, prostate, kidney). His laboratory investigates mechanisms of epigenetic dysregulation in prostate and bladder cancer and is developing novel circulating biomarkers using integrated genomics.